Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Tipranks - Sat Mar 7, 5:26AM CST

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Omada Health, Inc. (OMDA – Research Report), Progyny (PGNY – Research Report) and Owlet (OWLT – Research Report) with bullish sentiments.

Claim 70% Off TipRanks Premium

Omada Health, Inc. (OMDA)

In a report released today, Ryan MacDonald from Needham reiterated a Buy rating on Omada Health, Inc., with a price target of $28.00. The company’s shares closed last Thursday at $13.60.

According to TipRanks.com, MacDonald has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -10.4% and a 36.1% success rate. MacDonald covers the Technology sector, focusing on stocks such as ODDITY Tech Ltd. Class A, Waystar Holding Corp., and Duolingo. ;'>

Omada Health, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $24.71, an 83.0% upside from current levels. In a report issued on February 23, Evercore ISI also maintained a Buy rating on the stock with a $25.00 price target.

See today’s best-performing stocks on TipRanks >>

Progyny (PGNY)

BTIG analyst David Larsen maintained a Buy rating on Progyny yesterday and set a price target of $30.00. The company’s shares closed last Thursday at $17.62, close to its 52-week low of $13.39.

According to TipRanks.com, Larsen ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -10.5% and a 29.6% success rate. Larsen covers the Healthcare sector, focusing on stocks such as BrightSpring Health Services, Inc., Lifestance Health Group, and Hims & Hers Health. ;'>

Progyny has an analyst consensus of Strong Buy, with a price target consensus of $29.00, a 64.1% upside from current levels. In a report issued on February 23, Barclays also maintained a Buy rating on the stock with a $29.00 price target.

Owlet (OWLT)

William Blair analyst Andrew Brackmann reiterated a Buy rating on Owlet today and set a price target of $11.75. The company’s shares closed last Thursday at $11.75.

According to TipRanks.com, Brackmann is a 4-star analyst with an average return of 14.8% and a 52.5% success rate. Brackmann covers the Healthcare sector, focusing on stocks such as BillionToOne, Inc. Class A, Adaptive Biotechnologies, and Tempus AI, Inc. Class A. ;'>

Owlet has an analyst consensus of Strong Buy, with a price target consensus of $16.92.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).